Osteoarthritis and Bone Disorders News

Discrepancies between clinical practice guideline documents highlight the over-arching controversies in osteoporosis management, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

A reminder of some common and not-so-common clinical scenarios can make every rheumatologist more capable of delivering optimal patient care, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

Among patients with arthritis, receiving exercise recommendations from a physician is “critical” to meeting physical activity guidelines and relieving symptom burden, regardless of race and ethnicity, researchers noted in BMC Public Health.

Clinicians need to be aware of the contents of the June 3 memo from the FDA regarding use of human cell and tissue products and must realize that the guidance issued Nov. 15, 2017, has not changed, according to a regulatory consultant.

It will be “many years” before any new pharmacologic osteoporosis therapies are approved, as there are currently no new drugs in phase 2 or 3 development, according to a speaker at the 2021 Congress of Clinical Rheumatology-East meeting.

What is Paget’s? Why is it declining across much of the globe? Find out, plus hear an interview with the head of the center for osteoporosis and metabolic bone disease at Cleveland Clinic, Chad Deal, MD.

Just one-third of women older than 65 years were screened for osteoporosis at an internal medicine clinic, and one-third of those diagnosed were untreated, noted a speaker at the 2021 North American Young Rheumatology Investigator Forum.

A daily 300 mg dose of tramadol — but not 100 or 200 mg doses — surpassed placebo in improving pain and function related to hip or knee osteoarthritis, but was linked to increasing adverse events, researchers noted in Arthritis Care & Research.

Approximately 18% of patients in a rheumatic disease registry used cannabis in 2019, up from 6.3% in 2014, with the highest prevalence occurring in states where its use is legal, according to data published in Arthritis Care & Research.

Patients with rheumatoid arthritis who receive even low daily doses of glucocorticoids are at a 59% increased risk for clinical vertebral fracture, according to data published in Rheumatology.